Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT1X small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MT1X small interfering RNA is an experimental RNA interference (RNAi) agent designed to specifically silence the expression of the metallothionein 1X (MT1X) gene. MT1X is a member of the metallothionein family, which consists of low-molecular-weight, cysteine-rich proteins involved in metal ion homeostasis, detoxification, and protection against oxidative stress. In the context of oncology, particularly non-small cell lung cancer (NSCLC), MT1X has been identified as a metastasis-related gene (MRG) that promotes the migration and invasion of cancer cells. By mediating the degradation of MT1X mRNA, this siRNA inhibits the production of the MT1X protein, thereby suppressing the metastatic potential of lung cancer cell lines. It is primarily used as a research tool to validate MT1X as a potential therapeutic target or biomarker for metastatic lung cancer.
- Other names
- MT1X siRNAMT-1X siRNAMT 1X siRNAmetallothionein 1X small interfering RNAmetallothionein1X small interfering RNAmetallothionein-1X small interfering RNAsi-MT1Xsi-MT-1Xsi-MT 1X
02
Targets
MT1X (Metallothionein 1X)
Beyond the preview
Go deeper on MT1X small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT1X small interfering RNA.